Search

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2025

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Show Description +

Dr. Kuppermann highlights the phase 2a data from the SIGLEC trial of AVD-104 (Aviceda) for geographic atrophy, including a reduced lesion growth rate of 40% at 3 months in eyes treated with the two higher doses.

Posted: 5/17/2025

Keywords:

AVD-104

•

Avecida

•

retina-meeting-recap

•

Clinical Trials

•

Geographic Atrophy (GA)

Up Next

Real-World Data for 8 mg Aflibercept

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Treating DR with Axitinib

Treating DR with Axitinib

Neal S. Shah, MD

Phase 2 Data on Gene Therapy for AMD

Phase 2 Data on Gene Therapy for AMD

Christine Kay, MD

OCS-01 (Oculis) in DME: A Phase 3 Update

OCS-01 (Oculis) in DME: A Phase 3 Update

Carl Danzig, MD

Gene Therapy for Wet AMD: New Phase 2 Data

Gene Therapy for Wet AMD: New Phase 2 Data

Dante Pieramici MD

Surgical Pearls for Sickle Cell Retinopathy

Surgical Pearls for Sickle Cell Retinopathy

Jennifer I. Lim, MD

Dosing Considerations with 8 mg Aflibercept

Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

Pegcetacoplan in the Real World: Year 1

Pegcetacoplan in the Real World: Year 1

Mengxi Shen, MD, PhD

Back to All Videos

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Dr. Kuppermann highlights the phase 2a data from the SIGLEC trial of AVD-104 (Aviceda) for geographic atrophy, including a reduced lesion growth rate of 40% at 3 months in eyes treated with the two higher doses.

Posted: 5/17/2025

Keywords:

AVD-104

•

Avecida

•

retina-meeting-recap

•

Clinical Trials

•

Geographic Atrophy (GA)

Please log in to leave a comment.

More From ARVO: 2025 Coverage

Real-World Data for 8 mg Aflibercept

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Treating DR with Axitinib

Treating DR with Axitinib

Neal S. Shah, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2025.